Effective treatment against<unk>  continues to present a challenge to modern medicine - as do many other fungal infections. It is still being researched and can vary depending on the localization and type of infection. Factors like immunodeficiency can significantly hinder the chances of a successful outcome. Studies suggest Voriconazole to be effective as clinical treatment for infections caused by S. apiospermum. A study of 107 patients with saw the treatment successfully working in 57% in patients infected with<unk>  with best effects in localized S. apiospermum skin and bone infections. A 2003 review confirms its effectiveness for treating invasive mycosis of S. apiospermum while also citing evidence for efficacy of ravuconazole. A 2007 case report likewise shows the effectiveness of voriconazole in a renal transplant patient with disseminated<unk> . In cases of S. apiospermum-caused mycetoma, a treatment constituting a combination of surgery and terbinafine was reported to be effective in 2017. An immunocompromised patient suffering from an intense subcutaneous infection in his right leg was successfully treated using this method. S. prolificans treatment presents a more significant challenge due to its wider array of antifungal resistance. Localized limb infections might require extensive surgery or even amputation. A review of 162 cases of S. prolificans infection found no association with antifungal treatment (using then-currently available medications) and reduced risk of death. One study, however, argued for the efficiency of combination therapy using voriconazole and terbinafine to cure an orthopedic infection in a non-immunocompromised host without the need for a radical surgery. More resent medical advances show hope for more efficient antifungal therapies, however, as novel drugs like Ibrexafungerp - a glucan synthase inhibitor - is somewhat effective in treating S. prolificans infections. Another drug, Fosmanogepix, another fungal enzyme inhibitor, showed in vitro efficacy as treatment for<unk>  (including S. prolificans). Olorofim, a new dihydroorotate dehydrogenase inhibitor - which disrupts pyrimidine biosynthesis, - is also deserving of the reader's attention as it showed efficacy against both S. prolificans and S. apiospermum as well as other fungi known to be universally resistant to known antifungal medications.
Scedosporiosis
Protothecosis
African histoplasmosis
Botryomycosis
Zygomycosis
Otomycosis
Toxoplasmosis
Dermatomycosis